DiscGenics is a biopharmaceutical company focused on developing regenerative therapies aimed at alleviating pain and restoring function in patients with diseases of the spine. Its product candidate IDCT is a homologous, allogeneic, injectable cell therapy for the treatment of patients with degenerative disc disease.